InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 28 November 2023

This Phase I/II trial is trying to understand how safe and tolerable a new targeted therapy drug (EMB-06) is in people who have multiple myeloma that has come back or is resistant to other treatmentA First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Recurrent or Refractory Multiple Myeloma

Clinical summary


This trial has one experimental arm split into two phases. In Phase 1, participants will receive EMB-06 once weekly (intravenously) at different ascending dose levels. In Phase 2, participants will receive EMB-06 once weekly (intravenously) at a dose level (RP2D).


This trial is treating patients with multiple myeloma.


Blood Cancers Haematological





More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.

Scientific Title

A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Recurrent or Refractory Multiple Myeloma



  • Able to understand and willing to sign the informed consent form (ICF)
  • Patients who have been diagnosed with multiple myeloma according to IMWG diagnostic criteria 2014 and have relapsed or refractory multiple myeloma with at least one measurable lesion.
  • The patient must have received at least two lines (for patients in the US, at least three lines which should include anti-CD38 antibody) of prior antimyeloma therapies, and must have received treatment with proteasome inhibitors, immunomodulatory agents, and if accessible, an anti-CD38 targeting monoclonal antibody.
  • ECOG performance status 0 or 1 for phase I, and ≤2 for phase II.
  • Adequate organ function and reasonable laboratory test results to participate in the trial.
  • Highly effective contraception


  • Life expectancy is less than 3 months.
  • Patient participated in any other clinical study within 1 month prior to enrollment in this clinical study.
  • Patients with ongoing AE.
  • Previously treated with any BCMA-targeted therapy.(Exception: in Phase 2 portion, up to 10 patients who have received prior anti-BCMA ADC or BCMA targeted CAR-T can be enrolled)
  • History of allogeneic stem cell transplantation.
  • Previously treated with the following anti-tumor therapy (prior to first dosing of EMB-06)

    1. Treated with monoclonal antibody for multiple myeloma within 28 days
    2. Treated with proteasome inhibitors within 14 days
    3. Treated with immunomodulatory agents within 14 days
    4. Treated with cytotoxic therapy within 14 days
    5. Received investigational drug within 28 days or at least 5 half-lives, whichever is shorter (if a, b, c, d not applicable)
    6. Received radiotherapy within 21 days. Except that the radiation portal covered ≤ 5% of the bone marrow reserve, the patient will be eligible to participate in the study regardless of the end date of radiation therapy
    7. Plasmapheresis within 7 days
  • Patient received autologous stem cell transplantation within 12 weeks prior to the start of study treatment.
  • Active or historically multiple myeloma related central nervous system involvement.
  • Patients requiring high dose of systemic treatment with corticosteroids.
  • Patients with active infections, including COVID-19, hepatitis, etc..
  • History of severe allergic reactions
  • Patients with severe or uncontrolled cardiovascular disorder requiring treatment
  • Pre-existing other serious medical conditions


  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.


  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.